Latest news with #petosemtamab
Yahoo
25-05-2025
- Business
- Yahoo
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110. The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released. The drugs are intended to treat recurrent or metastatic Head and neck squamous cell carcinoma (HNSCC). Presented at the American Society of Clinical Oncology (ASCO), Merus' updated data included findings from an analysis of 43 evaluable patients conducted on February 27, 2025. With a confirmed Objective Response Rate (ORR) of 63%, the study demonstrated robust and long-lasting responses. Notably, a 79% survival rate was shown by the 12-month Overall Survival data. The standard of care for pembrolizumab, which carries a reported survival rate of roughly 50–59%, compares favorably to this. The market's response to the ASCO presentation indicates that petosemtamab's clinical potential to take the HNSCC treatment landscape to new heights is well-supported. The price target increase and revised estimates also demonstrate growing investor confidence in the drug's prospects. Evan David Seigerman of BMO Capital backed this assessment after the approval probability rose from 85% to 90%, pointing to favorable safety data. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT
On Friday, BofA increased its price target for Merus (NASDAQ:MRUS) to $92 from $70, while maintaining a Buy rating on the stock. The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma/HNSCC. The trial achieved a 12-month objective survival rate of 79% in its full cohort. A microscope with biomedical samples, highlighting the research efforts of the company. The survival rate surpasses historical benchmarks for pembrolizumab monotherapy, which typically range from 50% to 59% in the same patient population. It also well exceeds the 50%-60% range that BofA's medical checks had indicated would constitute good data. BofA believes that the data positions the peto + pembr combination as a potentially best-in-class treatment option for patients with HNSCC. The promising interim data from the Phase 2 trial, revealed at the ASCO Annual Meeting, showed a 63% overall response rate among 43 evaluable patients, which included 6 complete responses and 21 partial responses. The median progression-free survival was 9 months, and responses were observed across various PD-L1 levels, with 14 responding patients still on treatment at the data cutoff. Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that primarily develops antibody therapeutics in the Netherlands. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT
On Friday, BofA increased its price target for Merus (NASDAQ:MRUS) to $92 from $70, while maintaining a Buy rating on the stock. The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma/HNSCC. The trial achieved a 12-month objective survival rate of 79% in its full cohort. A microscope with biomedical samples, highlighting the research efforts of the company. The survival rate surpasses historical benchmarks for pembrolizumab monotherapy, which typically range from 50% to 59% in the same patient population. It also well exceeds the 50%-60% range that BofA's medical checks had indicated would constitute good data. BofA believes that the data positions the peto + pembr combination as a potentially best-in-class treatment option for patients with HNSCC. The promising interim data from the Phase 2 trial, revealed at the ASCO Annual Meeting, showed a 63% overall response rate among 43 evaluable patients, which included 6 complete responses and 21 partial responses. The median progression-free survival was 9 months, and responses were observed across various PD-L1 levels, with 14 responding patients still on treatment at the data cutoff. Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that primarily develops antibody therapeutics in the Netherlands. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110. The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released. The drugs are intended to treat recurrent or metastatic Head and neck squamous cell carcinoma (HNSCC). Presented at the American Society of Clinical Oncology (ASCO), Merus' updated data included findings from an analysis of 43 evaluable patients conducted on February 27, 2025. With a confirmed Objective Response Rate (ORR) of 63%, the study demonstrated robust and long-lasting responses. Notably, a 79% survival rate was shown by the 12-month Overall Survival data. The standard of care for pembrolizumab, which carries a reported survival rate of roughly 50–59%, compares favorably to this. The market's response to the ASCO presentation indicates that petosemtamab's clinical potential to take the HNSCC treatment landscape to new heights is well-supported. The price target increase and revised estimates also demonstrate growing investor confidence in the drug's prospects. Evan David Seigerman of BMO Capital backed this assessment after the approval probability rose from 85% to 90%, pointing to favorable safety data. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None.
